Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
24 févr. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the...
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
27 déc. 2018 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial...